Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.67 |
| ▸ | MAOA | P21397 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086718 | 0.90 | MAOB (0.61) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1633991 | 0.88 | NR4A2 (0.65) | KMT2A | |
| SCHEMBL31215373 | 0.88 | NR4A2 (0.65) | KMT2A | |
| SCHEMBL2087954 | 0.85 | MAOB (0.71) | MAOBMAOA | |
| SCHEMBL955309 | 0.85 | MAOB (0.51) | MAOBKMT2ASMN1; SMN2SLC22A12 | |
| SCHEMBL2089424 | 0.84 | MAOB (0.69) | MAOBMAOASMN1; SMN2 | |
| SCHEMBL1634331 | 0.84 | TDP1 (0.52) | MAOBKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL235381 | 0.84 | MAOB (0.48) | MAOBMAOASMN1; SMN2SLC22A12 | |
| SCHEMBL237424 | 0.84 | MAOB (0.48) | MAOBMAOASMN1; SMN2SLC22A12 | |
| SCHEMBL1437471 | 0.83 | MAOB (0.68) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285777-B1 | SYNTHESIS OF 4-[3-(2,6-DIMETHYLBENZYLOXY)PHENYL]-4-OXOBUTANOIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2016-09-07 | — | — | EP | claimed |
| US-8703991-B2 | Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-04-22 | — | — | US | claimed |
| US-8664433-B2 | Synthesis of 4-[3-(2,6-dimethylbenzyloxy)phenyl]-4-oxobutanoic acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-03-04 | — | — | US | claimed |
| US-20120004442-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-01-05 | — | — | US | claimed |
| EP-2365746-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | Wellstat Therapeutics Corporation (US) | 2011-09-21 | — | — | EP | claimed |
| US-20110201838-A1 | SYNTHESIS OF 4-[3-(2,6-DIMETHYLBENZYLOXY)PHENYL]-4-OXOBUTANOIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-08-18 | — | — | US | claimed |
| WO-2010053910-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-05-14 | — | — | WO | claimed |
| WO-2009137381-A1 | SYNTHESIS OF 4-[3-(2,6-DIMETHYLBENZYLOXY)PHENYL]-4-OXOBUTANOIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-11-12 | — | — | WO | claimed |
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2285777-B1 | SYNTHESIS OF 4-[3-(2,6-DIMETHYLBENZYLOXY)PHENYL]-4-OXOBUTANOIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | disclosed |
| US-8829058-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-09-09 | — | — | US | disclosed |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-05-20 | — | — | US | disclosed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885MAOA 1265/4885KMT2A 3364/4885 |
| US-20120004442-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | PGD, HPD, MLYCD | MAOB 684/4885MAOA 1278/4885KMT2A 2740/4885 |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885MAOA 1265/4885KMT2A 3364/4885 |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885MAOA 1265/4885KMT2A 3364/4885 |
| US-20110201838-A1 | SYNTHESIS OF 4-[3-(2,6-DIMETHYLBENZYLOXY)PHENYL]-4-OXOBUTANOIC ACID | HPD, EIF4B, MVD | MAOB 223/4885MAOA 1091/4885KMT2A 2879/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885MAOA 1265/4885KMT2A 3364/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885MAOA 1265/4885KMT2A 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.